EPO
Selected indexed studies
- EPO and EPO-Receptor System as Potential Actionable Mechanism for the Protection of Brain and Heart in Refractory Epilepsy and SUDEP. (Curr Pharm Des, 2020) [PMID:32072891]
- Epo-C12 inhibits peroxiredoxin 1 peroxidase activity. (Bioorg Med Chem, 2021) [PMID:34015702]
- Physiology and pathophysiology of renal erythropoietin-producing cells. (J Formos Med Assoc, 2018) [PMID:29655605]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- EPO and EPO-Receptor System as Potential Actionable Mechanism for the Protection of Brain and Heart in Refractory Epilepsy and SUDEP. (2020) pubmed
- Epo-C12 inhibits peroxiredoxin 1 peroxidase activity. (2021) pubmed
- Physiology and pathophysiology of renal erythropoietin-producing cells. (2018) pubmed
- Nonrenal regulation of EPO synthesis. (2009) pubmed
- Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events. (2014) pubmed
- EPO-modified bone marrow MSCs alleviate asthma inflammation through enhanced mitochondrial activation and transfer by upregulating HO-1. (2025) pubmed
- Rethinking EPO: A Paradigm Shift in Oncology? (2025) pubmed
- Rational design of selective bispecific EPO-R/CD131 agonists. (2025) pubmed
- Rational design of selective bispecific EPO-R/CD131 agonists. (2025) pubmed
- Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment. (2012) pubmed